Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 97

1.

Recovery of brain biomarkers following peroxisome proliferator-activated receptor agonist neuroprotective treatment before ischemic stroke.

Gelé P, Vingtdeux V, Potey C, Drobecq H, Ghestem A, Melnyk P, Buée L, Sergeant N, Bordet R.

Proteome Sci. 2014 May 6;12:24. doi: 10.1186/1477-5956-12-24. eCollection 2014.

PMID:
24944524
[PubMed]
Free PMC Article
2.

Neuroprotection against focal ischemic brain injury by the peroxisome proliferator-activated receptor-gamma agonist rosiglitazone.

Luo Y, Yin W, Signore AP, Zhang F, Hong Z, Wang S, Graham SH, Chen J.

J Neurochem. 2006 Apr;97(2):435-48. Epub 2006 Mar 15.

PMID:
16539667
[PubMed - indexed for MEDLINE]
3.

Neuroprotective effects of pioglitazone in a rat model of permanent focal cerebral ischemia are associated with peroxisome proliferator-activated receptor gamma-mediated suppression of nuclear factor-κB signaling pathway.

Zhang HL, Xu M, Wei C, Qin AP, Liu CF, Hong LZ, Zhao XY, Liu J, Qin ZH.

Neuroscience. 2011 Mar 10;176:381-95. doi: 10.1016/j.neuroscience.2010.12.029. Epub 2010 Dec 24.

PMID:
21185913
[PubMed - indexed for MEDLINE]
4.

Cross-talk between peroxisome proliferator-activated receptor (PPAR) alpha and liver X receptor (LXR) in nutritional regulation of fatty acid metabolism. II. LXRs suppress lipid degradation gene promoters through inhibition of PPAR signaling.

Ide T, Shimano H, Yoshikawa T, Yahagi N, Amemiya-Kudo M, Matsuzaka T, Nakakuki M, Yatoh S, Iizuka Y, Tomita S, Ohashi K, Takahashi A, Sone H, Gotoda T, Osuga J, Ishibashi S, Yamada N.

Mol Endocrinol. 2003 Jul;17(7):1255-67. Epub 2003 May 1.

PMID:
12730332
[PubMed - indexed for MEDLINE]
5.

Differential gene expression in mouse primary hepatocytes exposed to the peroxisome proliferator-activated receptor alpha agonists.

Guo L, Fang H, Collins J, Fan XH, Dial S, Wong A, Mehta K, Blann E, Shi L, Tong W, Dragan YP.

BMC Bioinformatics. 2006 Sep 6;7 Suppl 2:S18.

PMID:
17118139
[PubMed - indexed for MEDLINE]
Free PMC Article
6.

Quantitative proteomic analysis of mouse liver response to the peroxisome proliferator diethylhexylphthalate (DEHP).

Macdonald N, Chevalier S, Tonge R, Davison M, Rowlinson R, Young J, Rayner S, Roberts R.

Arch Toxicol. 2001 Sep;75(7):415-24.

PMID:
11693183
[PubMed - indexed for MEDLINE]
7.

Atorvastatin and fenofibrate increase apolipoprotein AV and decrease triglycerides by up-regulating peroxisome proliferator-activated receptor-alpha.

Huang XS, Zhao SP, Bai L, Hu M, Zhao W, Zhang Q.

Br J Pharmacol. 2009 Oct;158(3):706-12. doi: 10.1111/j.1476-5381.2009.00350.x. Epub 2009 Aug 19.

PMID:
19694729
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

Orally administered oleoylethanolamide protects mice from focal cerebral ischemic injury by activating peroxisome proliferator-activated receptor α.

Zhou Y, Yang L, Ma A, Zhang X, Li W, Yang W, Chen C, Jin X.

Neuropharmacology. 2012 Aug;63(2):242-9. doi: 10.1016/j.neuropharm.2012.03.008. Epub 2012 Mar 28.

PMID:
22480617
[PubMed - indexed for MEDLINE]
9.
10.

PPAR: a new pharmacological target for neuroprotection in stroke and neurodegenerative diseases.

Bordet R, Ouk T, Petrault O, Gelé P, Gautier S, Laprais M, Deplanque D, Duriez P, Staels B, Fruchart JC, Bastide M.

Biochem Soc Trans. 2006 Dec;34(Pt 6):1341-6. Review.

PMID:
17073815
[PubMed - indexed for MEDLINE]
11.

A proteome analysis of livers from obese (ob/ob) mice treated with the peroxisome proliferator WY14,643.

Edvardsson U, Alexandersson M, Brockenhuus von Löwenhielm H, Nyström AC, Ljung B, Nilsson F, Dahllöf B.

Electrophoresis. 1999 Apr-May;20(4-5):935-42.

PMID:
10344269
[PubMed - indexed for MEDLINE]
12.

Fenofibrate, a peroxisome proliferator-activated receptor alpha agonist, exerts neuroprotective effects in traumatic brain injury.

Besson VC, Chen XR, Plotkine M, Marchand-Verrecchia C.

Neurosci Lett. 2005 Nov 4;388(1):7-12.

PMID:
16087294
[PubMed - indexed for MEDLINE]
13.

Microarray analysis of gene expression changes in mouse liver induced by peroxisome proliferator- activated receptor alpha agonists.

Yamazaki K, Kuromitsu J, Tanaka I.

Biochem Biophys Res Commun. 2002 Jan 25;290(3):1114-22.

PMID:
11798191
[PubMed - indexed for MEDLINE]
14.

Evaluation of the therapeutic potential of PPARalpha agonists for X-linked adrenoleukodystrophy.

Rampler H, Weinhofer I, Netik A, Forss-Petter S, Brown PJ, Oplinger JA, Bugaut M, Berger J.

Mol Genet Metab. 2003 Dec;80(4):398-407.

PMID:
14654352
[PubMed - indexed for MEDLINE]
15.

Peroxisome proliferator-activated receptor alpha (PPARalpha) agonists down-regulate alpha2-macroglobulin expression by a PPARalpha-dependent mechanism.

González MC, Corton JC, Cattley RC, Herrera E, Bocos C.

Biochimie. 2009 Aug;91(8):1029-35. doi: 10.1016/j.biochi.2009.05.007. Epub 2009 Jun 2.

PMID:
19497347
[PubMed - indexed for MEDLINE]
16.

Peroxisome proliferator-activated receptor-γ agonist 15d-prostaglandin J2 mediates neuronal autophagy after cerebral ischemia-reperfusion injury.

Xu F, Li J, Ni W, Shen YW, Zhang XP.

PLoS One. 2013;8(1):e55080. doi: 10.1371/journal.pone.0055080. Epub 2013 Jan 25.

PMID:
23372817
[PubMed - indexed for MEDLINE]
Free PMC Article
17.

Peroxisome proliferator-activated receptor (PPAR)-gamma positively controls and PPARalpha negatively controls cyclooxygenase-2 expression in rat brain astrocytes through a convergence on PPARbeta/delta via mutual control of PPAR expression levels.

Aleshin S, Grabeklis S, Hanck T, Sergeeva M, Reiser G.

Mol Pharmacol. 2009 Aug;76(2):414-24. doi: 10.1124/mol.109.056010. Epub 2009 May 29.

PMID:
19483106
[PubMed - indexed for MEDLINE]
Free Article
18.

Peroxisome proliferator-activated receptor (PPAR)β/δ, a possible nexus of PPARα- and PPARγ-dependent molecular pathways in neurodegenerative diseases: Review and novel hypotheses.

Aleshin S, Strokin M, Sergeeva M, Reiser G.

Neurochem Int. 2013 Oct;63(4):322-30. doi: 10.1016/j.neuint.2013.06.012. Epub 2013 Jun 25. Review.

PMID:
23811400
[PubMed - indexed for MEDLINE]
19.

PPARα is involved in the multitargeted effects of a pretreatment with atorvastatin in experimental stroke.

Ouk T, Potey C, Laprais M, Gautier S, Hanf R, Darteil R, Staels B, Duriez P, Bordet R.

Fundam Clin Pharmacol. 2014 Jun;28(3):294-302. doi: 10.1111/fcp.12035. Epub 2013 May 23.

PMID:
23701370
[PubMed - in process]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk